EGFR, HLA-G, CD70, c-MET, and NY-ESO1 As Potential Biomarkers in High Grade Epithelial Ovarian Carcinoma

Authors

Duc Vo
Yan Liu
Anil K Sood
Katy Rezvani
Amir A Jazaeri
Jinsong Liu

Publication Date

1-1-2024

Journal

Cancer Biomarkers

Abstract

High grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR expression is significantly correlated with family history and worse OS. HLA-G is associated with worse OS. To confirm the results of EGFR and HLA-G, a second separated cohort of 248 patients is used. Positive EGFR expression again shows worse OS, while HLA-G expression has worse prognostic trend. CD70 has a worse OS trend. C-MET and NY-ESO1 do not have any clinical correlations. EGFR can potentially serve as target in future clinical immune therapy trials.

Keywords

Humans, Female, Biomarkers, Tumor, Membrane Proteins, Proto-Oncogene Proteins c-met, ErbB Receptors, Carcinoma, Ovarian Epithelial, Middle Aged, Ovarian Neoplasms, Prognosis, Antigens, Neoplasm, HLA-G Antigens, Aged, Adult, Neoplasm Grading, Immunohistochemistry, Aged, 80 and over, EGFR, HLA-G, CD70, c-MET, NY-ESO1, survival

DOI

10.3233/CBM-230200

PMID

38250760

PMCID

PMC11091604

PubMedCentral® Posted Date

April 2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes